TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10594399

Group type: EXPERIMENTAL
Intervention: OAM b.d. (omeprazole 20 mg b.d., amoxycillin 1000 mg b.d., metronidazole 800 mg b.d.)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: OAM t.d.s. (omeprazole 40 mg o.d., amoxycillin 500 mg t.d.s., metronidazole 400 mg t.d.s.)
Number of subjects: 255
Study: 8214416

Group type: EXPERIMENTAL
Intervention: 2.0 mg of thyrotropin-releasing hormone (TRH) IV
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3116661

Group type: EXPERIMENTAL
Intervention: Fat (200 ml vegetable oil)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (200 ml glucose)
Number of subjects: 8
Study: 28442236

Group type: EXPERIMENTAL
Intervention: Low omega-3 index (lowest quartile)
Number of subjects: 1449

Group type: EXPERIMENTAL
Intervention: High omega-3 index (three upper quartiles)
Number of subjects: 1449

Group type: EXPERIMENTAL
Intervention: Adjusted omega-3 index
Number of subjects: 1449
Study: 27456376

Group type: EXPERIMENTAL
Intervention: Distress Thermometer and Problem List (DT&PL)
Number of subjects: 0
Study: 24206869

Group type: EXPERIMENTAL
Intervention: FRAX report
Number of subjects: 60

Group type: COMPARATOR
Intervention: CAROC report
Number of subjects: 60
Study: 22642607

Group type: EXPERIMENTAL
Intervention: Red laser therapy (660 nm) applied at three points directly on the episiotomy after suturing in a single session between 6-56 hours postpartum.
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Infrared laser therapy (780 nm) applied at three points directly on the episiotomy after suturing in a single session between 6-56 hours postpartum.
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group underwent all laser procedures excluding the emission of irradiation.
Number of subjects: 114
Study: 19960200

Group type: EXPERIMENTAL
Intervention: 30-day supplementation with a whey-based cysteine donor
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 27
Study: 18843428

Group type: EXPERIMENTAL
Intervention: Night-time hand positioning splint
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (splint used only during evaluations)
Number of subjects: 50
Study: 16009884

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (44-microg three times weekly)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (22-microg three times weekly)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Number of subjects: 368
Study: 11835748

Group type: EXPERIMENTAL
Intervention: Nonoperative treatment
Number of subjects: 77

Group type: COMPARATOR
Intervention: Surgical intraventricular drainage
Number of subjects: 77
Study: 10069556

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Buspirone and Placebo (combined analysis)
Number of subjects: 49
Study: 8674225

Group type: EXPERIMENTAL
Intervention: Overnight pulse oximetry in children undergoing adenotonsillectomy
Number of subjects: 255

Group type: COMPARATOR
Intervention: Overnight pulse oximetry in normal children
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Children undergoing adenotonsillectomy
Number of subjects: 255

Group type: COMPARATOR
Intervention: Normal population
Number of subjects: 255
Study: 1872023

Group type: EXPERIMENTAL
Intervention: Vaccine A (adsorbed tetanus toxoid, 69 IIU/0.5 ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaccine B (adsorbed tetanus toxoid, 212 IIU/0.5 ml)
Number of subjects: 0
Study: 6633106

Group type: EXPERIMENTAL
Intervention: Regimen I with platinum and bleomycin
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Regimen II with bleomycin, cyclophosphamide, methotrexate and 5‐fluorouracil
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Combined modality approach (including radiotherapy or surgery)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Follow-up duration
Number of subjects: 49
Study: 31701429

Group type: EXPERIMENTAL
Intervention: EGCG mouthwash (starting at 440 μmol/L, three times a day, maximum tolerated dose 2200 μmol/L)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: EGCG mouthwash
Number of subjects: 20
Study: 31475297

Group type: EXPERIMENTAL
Intervention: Metabolic surgery
Number of subjects: 13722

Group type: COMPARATOR
Intervention: Nonsurgical management
Number of subjects: 13722
Study: 27770628

Group type: EXPERIMENTAL
Intervention: Intravenous Dexamethasone 30 mg perioperatively
Number of subjects: 20

Group type: COMPARATOR
Intervention: No Dexamethasone (controls)
Number of subjects: 20
Study: 25937184

Group type: EXPERIMENTAL
Intervention: Steeper decline in eGFR in women
Number of subjects: 6999

Group type: EXPERIMENTAL
Intervention: Steeper decline in eGFR in men
Number of subjects: 6999

Group type: EXPERIMENTAL
Intervention: Declining kidney function in women accounting for competing risk of death
Number of subjects: 6999

Group type: EXPERIMENTAL
Intervention: Declining kidney function in men accounting for competing risk of death
Number of subjects: 6999
Study: 25109511

Group type: EXPERIMENTAL
Intervention: Test formulation (tianeptine sodium 12.5 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Reference formulation (Stablon®)
Number of subjects: 40
Study: 22806076

Group type: EXPERIMENTAL
Intervention: Whey protein (0.3 g/kg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (0.2 g/kg cornstarch maltodextrin + 0.1 g/kg sucrose)
Number of subjects: 17
Study: 19028462

Group type: EXPERIMENTAL
Intervention: Auditory Stroop task (dual-task condition)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Single-task performance (congruent vs. incongruent)
Number of subjects: 24
Study: 17523902

Group type: EXPERIMENTAL
Intervention: 0.02% ropivacaine instilled into the renal puncture site, nephrostomy tract, and skin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Saline instilled into the renal puncture site, nephrostomy tract, and skin (Control)
Number of subjects: 34
Study: 15358872

Group type: EXPERIMENTAL
Intervention: 1 day workshop
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: six individual sessions
Number of subjects: 0
Study: 11394466

Group type: EXPERIMENTAL
Intervention: Conventional stick electrode welding process (SMAW)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Wire welding process (FCAW)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Both SMAW and FCAW
Number of subjects: 7
Study: 9700034

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 750 microg/day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 1500 microg/day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 7862853

Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg at the beginning and 50 mg maintenance dose half-way through the session
Number of subjects: 30
Study: 2144705

Group type: EXPERIMENTAL
Intervention: Nicorandil 10 mg twice daily for 3 weeks, then 20 mg twice daily for 3 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg once daily for 3 weeks, then 100 mg once daily for 3 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 37
Study: 380608

Group type: EXPERIMENTAL
Intervention: Atropine (2.0 mg oral, 1.0 mg i.m.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyoscine (1.0 mg oral, 0.25-0.5 mg i.m.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycopyrronium (0.2 mg i.m.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31045427

Group type: EXPERIMENTAL
Intervention: Interviewer-administered condition (phone or in-person)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Self-administered condition (via the Assessment Center website)
Number of subjects: 277
Study: 27808596

Group type: EXPERIMENTAL
Intervention: Virtual reality based treadmill training (n=14)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Treadmill training (control group, n=11)
Number of subjects: 25
Study: 25645169

Group type: EXPERIMENTAL
Intervention: iCBT (internet-delivered cognitive behavior therapy)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 72
Study: 25530242

Group type: EXPERIMENTAL
Intervention: Afterschool intervention promoting water intake
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Implementation factors influencing water intake
Number of subjects: 20
Study: 22329753

Group type: EXPERIMENTAL
Intervention: Small incentive ($5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Large incentive ($50)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partisans with strong belief in their predictions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutrals
Number of subjects: 0
Study: 19458926

Group type: EXPERIMENTAL
Intervention: Eperisone 300 mg/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Baclofen 60 mg/day
Number of subjects: 80
Study: 18085137

Group type: EXPERIMENTAL
Intervention: SHAO's 'five needling methods'
Number of subjects: 210

Group type: COMPARATOR
Intervention: Routine needling method
Number of subjects: 210
Study: 15366324

Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ephedrine (0.25, 0.5, and 1 mg x kg(‐1))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11336107

Group type: EXPERIMENTAL
Intervention: Vitamin C (2 g, intravenous)
Number of subjects: 10
Study: 9537847

Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 187

Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 187
Study: 8033487

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buspirone (20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2898319

Group type: EXPERIMENTAL
Intervention: Controlled-release naproxen (750 mg or 1000 mg once-a-day)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Standard marketed naproxen (375 mg or 500 mg twice-a-day)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Controlled-release naproxen (750 mg or 1000 mg once-a-day) during open-label phase
Number of subjects: 404
Study: 31081951

Group type: EXPERIMENTAL
Intervention: Tongue-thrusting group (n=8)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Non-thrusting group (n=3)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Healthy group (n=8)
Number of subjects: 11
Study: 28595089

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 25636011

Group type: EXPERIMENTAL
Intervention: HalfLytely© 1 L × 2 doses and bisacodyl 5 mg delayed release tablets × 2 tablets (Protocol 1)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: MiraLAX® 5 tablespoons × 2 doses and bisacodyl 5 mg tablets × 2 tablets (Protocol 2)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: MoviPrep 1 L × 2 doses (Protocol 3)
Number of subjects: 209
Study: 23486859

Group type: EXPERIMENTAL
Intervention: HPV‐16/18 vaccine
Number of subjects: 334

Group type: COMPARATOR
Intervention: Placebo (Al(OH)3 control)
Number of subjects: 334
Study: 21244304

Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Various dystonia medications (anticholinergic agents, baclofen, clonazepam, tetrabenazine, clozapine)
Number of subjects: 0
Study: 19266393

Group type: EXPERIMENTAL
Intervention: Stretch
Number of subjects: 10

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 10
Study: 18632034

Group type: EXPERIMENTAL
Intervention: Educational leaflet on diabetes and LRTIs and UTIs
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no leaflet)
Number of subjects: 200
Study: 14992906

Group type: EXPERIMENTAL
Intervention: Neutrophil-filtered blood cardioplegia/reperfusion
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard blood cardioplegia/reperfusion (control group)
Number of subjects: 160
Study: 11486568

Group type: EXPERIMENTAL
Intervention: Cold pressor test (CPT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No cold pressor test (control)
Number of subjects: 30
Study: 9014973

Group type: EXPERIMENTAL
Intervention: tissue-type plasminogen activator (t-PA)
Number of subjects: 3526

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 3526

Group type: EXPERIMENTAL
Intervention: CABG within the first 4 days of randomization
Number of subjects: 3526

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 3526
Study: 7681050

Group type: EXPERIMENTAL
Intervention: Medium dose rate brachytherapy (1000 cGy at 5 mm depth for three fractions)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: High dose rate brachytherapy (1000 cGy at 10 mm depth for three fractions)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: High dose rate brachytherapy (750 cGy at 10 mm depth for three fractions)
Number of subjects: 318
Study: 3536050

Group type: EXPERIMENTAL
Intervention: Thymostimulin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (no thymostimulin)
Number of subjects: 42
Study: 31095973

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham tDCS (Control)
Number of subjects: 38
Study: 28851233

Group type: EXPERIMENTAL
Intervention: Incremental Shuttle Walk Test (ISWT)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Endurance Shuttle Walk Test (ESWT)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Participant characteristics (age, lung function, nadir SpO2, end-test dyspnoea)
Number of subjects: 87
Study: 27189687

Group type: EXPERIMENTAL
Intervention: Better Nights/Better Days intervention (five-session manual and weekly telephone coach support)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Actigraphy results
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Parent satisfaction ratings
Number of subjects: 61
Study: 25590463

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) with a focus on cognitive restructuring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) focusing on Stress Management
Number of subjects: 0
Study: 23001395

Group type: EXPERIMENTAL
Intervention: Acute NaHCO3 loading (AL)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Serial NaHCO3 loading (SL)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo loading condition (P)
Number of subjects: 8
Study: 20096466

Group type: EXPERIMENTAL
Intervention: Combined treatment (pharmacotherapy and adjunctive psychosocial treatment based on a cognitive‐behavioral model)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control treatment (standard drug treatment)
Number of subjects: 20
Study: 17497570

Group type: EXPERIMENTAL
Intervention: Sensorimotor training (SMT)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Strength training (ST)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 17
Study: 16263860

Group type: EXPERIMENTAL
Intervention: Psychotherapy treatment over 12 to 16 weeks
Number of subjects: 88
Study: 12411067

Group type: EXPERIMENTAL
Intervention: Iodized salt with an iodine concentration of 25 mg/kg (Group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iodized salt purchased from the market (Group B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iodized salt purchased from the market + iodized oil capsules containing 400 mg iodine (Group C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study: 10219530

Group type: EXPERIMENTAL
Intervention: Diabetmin Retard
Number of subjects: 12

Group type: COMPARATOR
Intervention: Glucophage Retard
Number of subjects: 12
Study: 7666878

Group type: EXPERIMENTAL
Intervention: Chiropractors
Number of subjects: 1633

Group type: EXPERIMENTAL
Intervention: Orthopedic surgeons
Number of subjects: 1633

Group type: EXPERIMENTAL
Intervention: Primary care practitioners
Number of subjects: 1633

Group type: EXPERIMENTAL
Intervention: HMO providers
Number of subjects: 1633

Group type: COMPARATOR
Intervention: All practitioners
Number of subjects: 1633
Study: 1982830

Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.c.) self‐administered R‐EPO (starting dose 92 +/‐ 35 U/kg/week) two times a week
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intraperitoneal (i.p.) R‐EPO (170 +/‐ 42 U/kg/week) thrice weekly
Number of subjects: 16
Study: 343967

Group type: EXPERIMENTAL
Intervention: Floctafenine 200 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral meperidine 75 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral propoxyphene 65 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Floctafenine
Number of subjects: 40
Study: 30732471

Group type: EXPERIMENTAL
Intervention: Adjunctive anti-radiation shield under the angiographic table (group 2)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Standard arrangement (group 1)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Two different under-the-table shields (small curtain and drape)
Number of subjects: 157
Study: 27317032

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (100 mg rectally)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Ceftazidime (1 g intravenously)
Number of subjects: 272
Study: 25611308

Group type: EXPERIMENTAL
Intervention: 0.5% cis‐urocanic acid (cis‐UCA) eye drops
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 2.5% cis‐urocanic acid (cis‐UCA) eye drops
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Cis‐UCA concentrations in plasma
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Cis‐UCA excretion in urine
Number of subjects: 37
Study: 24218460

Group type: EXPERIMENTAL
Intervention: Vitamin E (50 IU/kg as dl‐α‐tocopheryl acetate)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo (sterile water)
Number of subjects: 93
Study: 21088862

Group type: EXPERIMENTAL
Intervention: Active LEDT (69 LEDs with wavelengths 660/850 nm, 10/30 mW of output power, 30 s of irradiation time per point, total of 41.7 J irradiated per point)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cold Water Immersion Therapy (CWIT) (5°C of temperature [SD ±1°])
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo LEDT
Number of subjects: 6
Study: 19372330

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: New combined EEG/AEP indicator
Number of subjects: 15

Group type: COMPARATOR
Intervention: Former 'detector of consciousness'
Number of subjects: 15
Study: 16394188

Group type: EXPERIMENTAL
Intervention: Arabic versions of standard scales for assessing computer attitudes
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Gender, years of teaching experience, computer use, computer experience
Number of subjects: 443
Study: 14618332

Group type: EXPERIMENTAL
Intervention: Senegalese sprinters (S)
Number of subjects: 28
Study: 11783762

Group type: EXPERIMENTAL
Intervention: Bic/Lac (25 mmol/L bicarbonate/15 mmol/L lactate)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Lac (35 mmol/L lactate)
Number of subjects: 31
Study: 9224307

Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Ethoglucid
Number of subjects: 443

Group type: COMPARATOR
Intervention: Transurethral resection alone
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 443
Study: 7962377

Group type: EXPERIMENTAL
Intervention: recFSH alone (group I)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: recFSH with buserelin intranasal spray (4 x 150 micrograms per day) in a short protocol (group II)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: recFSH with buserelin in a long protocol (group III)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: recFSH with triptorelin (3.75 mg i.m. in a long protocol) (group IV)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: recFSH with triptorelin (200 micrograms daily s.c. injections) (group V)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 50

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 50
Study: 3315606

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous anisoylated plasminogen streptokinase activator complex (APSAC)
Number of subjects: 0
Study: 31100091

Group type: EXPERIMENTAL
Intervention: First team players
Number of subjects: 119

Group type: COMPARATOR
Intervention: Reserves
Number of subjects: 119
Study: 29286560

Group type: EXPERIMENTAL
Intervention: Physical therapy and motivation-based intervention (n=33)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Usual care (n=40)
Number of subjects: 73
Study: 28043418

Group type: EXPERIMENTAL
Intervention: Pralidoxime (PAM) treatment guided by APACHE II scores and BuChE activity
Number of subjects: 46

Group type: COMPARATOR
Intervention: WHO's recommended PAM regimen
Number of subjects: 46
Study: 24639094

Group type: EXPERIMENTAL
Intervention: BFR-RT (20-30% 1-RM, knee extension and leg press)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-BFR training
Number of subjects: 0
Study: 21818576

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 19914662

Group type: EXPERIMENTAL
Intervention: Low fat diet (15% kcal), high fiber, soy protein supplemented diet
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low fat diet (15% kcal)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Western diet (40% kcal fat)
Number of subjects: 18
Study: 18805335

Group type: EXPERIMENTAL
Intervention: Standard treatment modified based on measurements of fraction of exhaled NO
Number of subjects: 546

Group type: COMPARATOR
Intervention: Standard treatment based on NAEPP guidelines (Control)
Number of subjects: 546
Study: 15224298

Group type: EXPERIMENTAL
Intervention: Retroinfusion-supported stenting (n = 23)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Bypass surgery (n = 21)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44